Systemic sclerosis & Raynaud's

Unveiling the clinical spectrum of ACA-positive SSC-ILD: not as benign as expected

Rheumatology (Oxford)Published Cross-sectional study

Authors' conclusion

ACA-positive SSc-ILD does not seem to have a more favourable long-term prognosis compared with other serological subsets.

Study context

Population
Patients with SSc-ILD by serological subset
Participants
76 / 54 / 147
Exposure
ACA-positive SSc-ILD vs ATA-positive and ACA/ATA-negative SSc-ILD
  • ACA-positiven = 76
  • ATA-positiven = 54
  • ACA/ATA-negativen = 147
Methodological detailsmulticentre, observational
  • Multicentre
  • Observational

Further findings

Time to ILD development · across the three groups

P = 0.389

Lung transplantation

Autologous haematopoietic stem cell transplantation

OutcomeACA-positiveATA-positiveACA/ATA-negativeP value
NYHA class III-IVAcross the three groups14.5%— withheld: not confirmed against the abstract— withheld: not confirmed against the abstractP = 0.017
pFVC/pDLCO ratioAcross the three groups— withheld: not confirmed against the abstract1.4— withheld: not confirmed against the abstractP = 0.016
ILD worsening (ATS criteria)14.5%— not stated in the abstract— not stated in the abstract

— not stated in the abstract

— withheld: the automatic checks could not confirm the value against the abstract

pFVC · across the three groups
P = 0.013
pFEV1/pFVC ratio · across the three groups
P = 0.004
pKCO · across the three groups
P = 0.008
pDLCO · not significant
P = 0.769
Overall survival · no significant differences across the three groups
P = 0.164

Lung transplantation

No significant differences in antifibrotic indication or advanced interventions

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Unveiling the clinical spectrum of ACA-positive SSC-ILD: not as benign as expected. Rheumatology (Oxford). Published 31 July 2025. doi:10.1093/rheumatology/keaf407

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.